LOS ANGELES, April 19, 2018 -- With April being Alcohol Awareness Month, studies show 83% of people who drink excessively received no advice or encouragement from family and friends to cut down their drinking. Women with drinking problems were much less likely than men to receive advice with only 11.7% of them encouraged to seek help.
Using alcohol is socially acceptable and often even encouraged, despite the very real risks of substance abuse and health issues. According to a study published in JAMA Psychiatry, a staggering 1 in 8 Americans struggle with alcohol abuse.
“Hearing from friends or family that they might need help with alcohol is one of the main factors in people seeking treatment. And the sooner they get help, the sooner they can go on with their lives with a healthier relationship with alcohol,” says Dr. Diane Rothon, Medical Director for alcohol recovery program Alavida Health.
Only 10% of addicts ever get treatment
“The key to helping Americans with alcohol use disorder lies in having open and honest conversations about alcohol, helping people identify they have a problem, and finding them the right type of help to treat their addiction,” Dr. Rothon says.
Once someone has identified that they need help, finding the right kind of treatment is the next step. There are plenty of options, from traditional 12-step programs like AA to more revolutionary treatments such as Alavida Health, a science-based treatment program that promotes controlled drinking therapy instead of abstinence and touts a 75% success rate.
About Alavida
Alavida Health is a science-based treatment program that combines non-addictive medication, behavioral therapy and technology to help people decrease or stop their consumption of alcohol. Alavida clients work with their doctor and therapist for typically four to six months and can access their doctors in person or virtually, making the access barrier-free. Available in North America since 2016, Alavida currently has offices in Canada and the USA. The treatment model has a success rate of over 75 percent, in line with a clinical study and 20 years of ongoing practice conducted in Finland. More information about Alavida and how treatment works can be found at www.alavida.co.
Contact:
Binu Koshy
Media Relations
P: 905-617-1988 / 1-888-315-8550
E: [email protected]
Christine Gomes
Marketing Manager
E: [email protected]


Samsung to Launch First Yongin Chip Plant by 2029 as South Korea Speeds Up Semiconductor Hub
Levi Strauss Raises 2026 Outlook After Q2 Earnings Beat, Shares Drop Despite Strong Results
SK Hynix Prices Record U.S. ADR Offering at $149 After $200 Billion Investor Demand
Elon Musk Says Anthropic Leads AI Race as Claude Models Challenge OpenAI
Morgan Stanley Names Marks & Spencer Top European Retail Pick, Sees Strong Upside
Sino Biopharm Stock Rises After AstraZeneca Licensing Deal, GSK Partnership Expansion
Morgan Stanley Says China’s Reusable Rocket Progress Poses Long-Term Challenge to SpaceX
SK Hynix Shares Drop After Strong Nasdaq Debut Despite $26 Billion ADR Listing
TSMC Q2 Revenue Surges 36% as AI Chip Demand Powers Growth Ahead of Earnings
Nippon Paint Reportedly Offers Up to €7.5 Billion for Akzo Nobel Decorative Paints Business
Stellantis Q2 Vehicle Shipments Rise 10% as North America Drives Growth
Oppenheimer Sees CNH Industrial as Top 2026 Agriculture Stock Pick on Dealer Consolidation Strategy
Kitron Q2 Revenue Beats Estimates as Defense Demand Lifts Growth
Samsung Chairman Lee Jae-yong Expected to Meet Nvidia CEO Jensen Huang on AI and Chip Partnership
Deutsche Bank Fined A$2 Million by ASIC Over OTC Derivatives Reporting Errors
OpenAI Executive Fidji Simo to Step Down Amid Health Challenges Ahead of IPO
BHP Faces Port Hedland Strike Threat as Iron Ore Export Risks Grow 



